Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG439

—

c86d7b71-0836-55fd-b560-6f547a86b2dd

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • ANGIOGENESIS+0.480
  • IL6_JAK_STAT3_SIGNALING+0.436
  • INTERFERON_ALPHA_RESPONSE+0.434
  • REACTIVE_OXYGEN_SPECIES_PATHWAY+0.426
  • INTERFERON_GAMMA_RESPONSE+0.393
  • INFLAMMATORY_RESPONSE+0.362
  • TNFA_SIGNALING_VIA_NFKB+0.352
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.341
  • COAGULATION+0.314
  • OXIDATIVE_PHOSPHORYLATION+0.294

Top 10 suppressed

  • E2F_TARGETS-0.368
  • G2M_CHECKPOINT-0.254
  • MITOTIC_SPINDLE-0.233
  • CHOLESTEROL_HOMEOSTASIS-0.184
  • SPERMATOGENESIS-0.169
  • MYC_TARGETS_V2-0.132
  • MYC_TARGETS_V1-0.102
  • PEROXISOME-0.053
  • DNA_REPAIR-0.047
  • WNT_BETA_CATENIN_SIGNALING-0.011

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant

#SampleCancer typeSubtypecos similarity
1MDT-AP-2021
medullo-epn-umap@date-based
MedMedulloblastoma0.916
2BS_C51RB0YR
brain-umap@2
low-grade glioma—0.883
3BS_VMQMGSJY
brain-umap@2
high-grade glioma—0.883
4BS_PQ6QEVE8
brain-umap@2
Ganglioglioma—0.876
5BS_M4TTKPNR
brain-umap@2
pilocytic astrocytoma—0.876
6TCGA-CV-7433-01A-11R-2132-07
head-neck@1
——0.872
7MDT-AP-0816
medullo-epn-umap@date-based
MedMedulloblastoma0.871
8BS_GYXSDZ56
brain-umap@2
pilocytic astrocytoma—0.868
9BS_YA8RBGD8
brain-umap@2
low-grade glioma—0.866
10841ae9cb-ae41-46f9-84ae-03c99fd4e6dd
colon-landscapes@1
——0.863

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 40 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
ANGIOGENESIS0.480Remibrutinib— uncovered
IL6_JAK_STAT3_SIGNALING0.436Inavolisib— uncovered
INTERFERON_ALPHA_RESPONSE0.434Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.426Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.393Idelalisib— uncovered
INFLAMMATORY_RESPONSE0.362Idelalisib— uncovered
TNFA_SIGNALING_VIA_NFKB0.352Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.341Inavolisib— uncovered
COAGULATION0.314Binimetinib— uncovered
OXIDATIVE_PHOSPHORYLATION0.294Remibrutinib— uncovered
ALLOGRAFT_REJECTION0.286Idelalisib— uncovered
HYPOXIA0.265Idelalisib— uncovered
IL2_STAT5_SIGNALING0.265Idelalisib— uncovered
COMPLEMENT0.241Inavolisib— uncovered
APICAL_SURFACE0.234Temsirolimus— uncovered
APICAL_JUNCTION0.225Inavolisib— uncovered
NOTCH_SIGNALING0.217Inavolisib— uncovered
GLYCOLYSIS0.211Inavolisib— uncovered
MYOGENESIS0.199Inavolisib— uncovered
UV_RESPONSE_DN0.194Inavolisib— uncovered